Financial & competing interests disclosure
The authors wish to acknowledge all co-authors of the FP7 collaborative project published in reference 5, which was supported by European Commission-granted TOLLerant H2020-MSC-ETN-642157 project, NIH grants R56 AI18797 and R01 AI104541, Inserm “Projet Ebola, I3M”. V Lotteau is a co-founder of EnyoPharma. The authors declare no financial competing interest. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.